FDA approves KalVista’s HAE drug after review delaynews2025-07-07T10:40:37+00:00July 7th, 2025|Endpoints News|
Roche-backed Chugai taps into longevity field with Pfizer-allied Geronews2025-07-07T07:00:46+00:00July 7th, 2025|Endpoints News|
European Commission fines Alchem, closes API ‘cartel’ investigation news2025-07-07T02:05:08+00:00July 7th, 2025|Endpoints News|
Apple Tree says its biotechs face ‘imminent collapse’; Advocates urge J&J to proceed with eye gene therapy; AbbVie buys in vivo CAR-T maker Capstan; and morenews2025-07-05T10:00:03+00:00July 5th, 2025|Endpoints News|
Judge rules against Trump administration’s removal of HHS web contentnews2025-07-03T16:31:09+00:00July 3rd, 2025|Endpoints News|
Novartis’ Cosentyx fails Phase 3 study for autoimmune diseasenews2025-07-03T15:07:04+00:00July 3rd, 2025|Endpoints News|
Cloudbreak’s shares stumble in Hong Kong debut; Sinovac squares off against activistnews2025-07-03T14:27:11+00:00July 3rd, 2025|Endpoints News|
Torrent Pharma’s $1.38B JB Chemicals takeover; Future Pak to buy Theratechnologiesnews2025-07-03T14:20:10+00:00July 3rd, 2025|Endpoints News|
The Trump administration is promoting wearable health devices — with or without evidencenews2025-07-03T13:30:44+00:00July 3rd, 2025|Endpoints News|
Number of megarounds drops 38% in first half as biotechs struggle against worsening slumpnews2025-07-03T12:28:26+00:00July 3rd, 2025|Endpoints News|
